Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies.

alectinib early-stage NSCLC induction lung cancer osimertinib perioperative

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
06 Aug 2024
Historique:
received: 19 07 2024
revised: 01 08 2024
accepted: 05 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

The recent advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint blockers (ICBs) in early-stage non-small cell lung cancer (NSCLC) has dramatically modified treatment strategies by improving the prognosis in this setting. Osimertinib and alectinib, both TKIs, have shown significant improvements in outcomes for patients with resected

Identifiants

DOI: 10.3390/cancers16162779 PMID: 39199552
pubmed: 39199552
pii: cancers16162779
doi: 10.3390/cancers16162779
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Pernelle Lavaud (P)

Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue Edouard Vaillant, 94805 Villejuif, France.
ORCID: 0000-0002-1286-5955

Martina Bortolot (M)

Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, 6229 ER Maastricht, The Netherlands.
Department of Medicine (DMED), University of Udine, 33100 Udine, Italy.

Lodovica Zullo (L)

Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue Edouard Vaillant, 94805 Villejuif, France.
ORCID: 0000-0002-1659-788X

David O'Reilly (D)

Medical Oncology, Beaumont Hospital, RCSI University of Health Sciences, D02 YN77 Dublin, Ireland.

Jarushka Naidoo (J)

Medical Oncology, Beaumont Hospital, RCSI University of Health Sciences, D02 YN77 Dublin, Ireland.
ORCID: 0000-0002-3470-8686

Giannis Mountzios (G)

Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, 11526 Athens, Greece.

Olaf Mercier (O)

Department of Thoracic Surgery, Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France.
ORCID: 0000-0002-4760-6267

Lizza E L Hendriks (LEL)

Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, 6229 ER Maastricht, The Netherlands.
ORCID: 0000-0002-3521-2535

Jordi Remon (J)

Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue Edouard Vaillant, 94805 Villejuif, France.
ORCID: 0000-0002-9462-875X

Classifications MeSH